BioCryst (BO1) AI Stock Analysis

Company Guidance

For 2026, BioCryst maintained ORLADEYO revenue guidance of $625 million to $645 million, increased total revenue guidance to $715 million to $730 million, and tightened full-year operating expense guidance to $415 million to $425 million; CareMed inventory typically ranges from 1 to 3 weeks of product, with the third-quarter inventory contribution in the upper-teens of millions of dollars expected to be a one-time benefit. The company expects approximately $30 million to $35 million of annualized savings once fully realized, with operating expenses in 2027 expected to decline further, and will provide formal 2027 guidance at the appropriate time. It expects navenibart top-line data through 12 months of therapy in the third quarter of next year, early BCX17.7 thousand clinical data by the end of this year, and said 20 to 25 percent in the primary IASI score should be a pretty good clinically meaningful endpoint; the pediatric market may be bigger than the 500 diagnosed and treated patients previously described, the long-term paid-rate goal is 85%, and the 2033 HAE franchise range described was about $1.4 billion to $2 billion.